Overcoming resistance to rapalogs in gliomas by combinatory therapies

Glioblastoma is the most common and aggressive brain tumor type, with a mean patient survival of approximately 1 year. Many previous analyses of the glioma kinome have identified key deregulated pathways that converge and activate mammalian target of rapamycin (mTOR). Following the identification and characterization of mTOR-promoting activity in gliomagenesis, data from preclinical studies suggested the targeting of mTOR by rapamycin or its analogs (rapalogs) as a promising therapeutic approach. However, clinical trials with rapalogs have shown very limited efficacy on glioma due to the development of resistance mechanisms. Analysis of rapalog-insensitive glioma cells has revealed increased activity of growth and survival pathways compensating for mTOR inhibition by rapalogs that are suitable for therapeutic intervention. In addition, recently developed mTOR inhibitors show high anti-glioma activity. In this review, we recapitulate the regulation of mTOR signaling and its involvement in gliomagenesis, discuss mechanisms resulting in resistance to rapalogs, and speculate on strategies to overcome resistance. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012).     

Identification and characterization of bi-thiazole-2,2′-diamines as kinase inhibitory scaffolds

Based on bioinformatics interrogation of the genome, > 500 mammalian protein kinases can be clustered within seven different groups. Of these kinases, the mitogen-activated protein kinase (MAPK) family forms part of the CMGC group of serine/threonine kinases that includes extracellular signal regulated kinases (ERKs), cJun N-terminal kinases (JNKs), and p38 MAPKs. With the JNKs considered attractive targets in the treatment of pathologies including diabetes and stroke, efforts have been directed to the discovery of new JNK inhibitory molecules that can be further developed as new therapeutics. Capitalizing on our biochemical understanding of JNK, we performed in silico screens of commercially available chemical databases to identify JNK1-interacting compounds and tested their in vitro JNK inhibitory activity. With in vitro and cell culture studies, we showed that the compound, 4′-methyl-N²-3-pyridinyl-4,5′-bi-1,3-thiazole-2,2′-diamine (JNK Docking (JD) compound 123, but not the related compound (4′-methyl-N ~ 2 ~ -(6-methyl-2-pyridinyl)-4,5′-bi-1,3-thiazole-2,2′-diamine (JD124), inhibited JNK1 activity towards a range of substrates. Molecular docking, saturation transfer difference NMR experiments and enzyme kinetic analyses revealed both ATP- and substrate-competitive inhibition of JNK by JD123. In characterizing JD123 further, we noted its ATP-competitive inhibition of the related p38-γ MAPK, but not ERK1, ERK2, or p38-α, p38-β or p38-δ. Further screening of a broad panel of kinases using 10 μM JD123, identified inhibition of kinases including protein kinase Bβ (PKBβ/Aktβ). Appropriately modified thiazole diamines, as typified by JD123, thus provide a new chemical scaffold for development of inhibitors for the JNK and p38-γ MAPKs as well as other kinases that are also potential therapeutic targets such as PKBβ/Aktβ.     

Colon tumour secretopeptidome: Insights into endogenous proteolytic cleavage events in the colon tumour microenvironment

The secretopeptidome comprises endogenous peptides derived from proteins secreted into the tumour microenvironment through classical and non-classical secretion. This study characterised the low-M_r (< 3 kDa) component of the human colon tumour (LIM1215, LIM1863) secretopeptidome, as a first step towards gaining insights into extracellular proteolytic cleavage events in the tumour microenvironment. Based on two biological replicates, this secretopeptidome isolation strategy utilised differential centrifugal ultrafiltration in combination with analytical RP-HPLC and nanoLC-MS/MS. Secreted peptides were identified using a combination of Mascot and post-processing analyses including MSPro re-scoring, extended feature sets and Percolator, resulting in 474 protein identifications from 1228 peptides (≤ 1% q-value, ≤ 5% PEP) — a 36% increase in peptide identifications when compared with conventional Mascot (homology ionscore thresholding). In both colon tumour models, 122 identified peptides were derived from 41 cell surface protein ectodomains, 23 peptides (12 proteins) from regulated intramembrane proteolysis (RIP), and 12 peptides (9 proteins) generated from intracellular domain proteolysis. Further analyses using the protease/substrate database MEROPS, (http://merops.sanger.ac.uk/), revealed 335 (71%) proteins classified as originating from classical/non-classical secretion, or the cell membrane. Of these, peptides were identified from 42 substrates in MEROPS with defined protease cleavage sites, while peptides generated from a further 205 substrates were fragmented by hitherto unknown proteases. A salient finding was the identification of peptides from 88 classical/non-classical secreted substrates in MEROPS, implicated in tumour progression and angiogenesis (FGFBP1, PLXDC2), cell–cell recognition and signalling (DDR1, GPA33), and tumour invasiveness and metastasis (MACC1, SMAGP); the nature of the proteases responsible for these proteolytic events is unknown. To confirm reproducibility of peptide fragment abundance in this study, we report the identification of a specific cleaved peptide fragment in the secretopeptidome from the colon-specific GPA33 antigen in 4/14 human CRC models. This improved secretopeptidome isolation and characterisation strategy has extended our understanding of endogenous peptides generated through proteolysis of classical/non-classical secreted proteins, extracellular proteolytic processing of cell surface membrane proteins, and peptides generated through RIP. The novel peptide cleavage site information in this study provides a useful first step in detailing proteolytic cleavage associated with tumourigenesis and the extracellular environment. This article is part of a Special Issue entitled: An Updated Secretome.     

藜磷酸肌醇5-磷酸酶基因(CaP5P)的表达分析和胁迫响应检测

植物通过多种信号途径感知外界环境变化,从而引发一系列的信号级联反应,其中磷脂信号途径起着重要的作用。本研究从藜盐胁迫差减文库中获得了一个EST05序列,利用RT-PCR检测了其在非生物胁迫下表达趋势,显示EST05序列在非生物胁迫下的表达有升高。随后利用RACE技术获得其全长编码序列,测序结果显示其与蓖麻(Ricinus communis) 的磷酸肌醇5-磷酸酶基因(P5P)的同源性达56%,遂将其命名为CaP5P。最后过量表达CaP5P在拟南芥中初步验证了功能,转基因植株表现对盐胁迫耐受性降低的趋势,呈现负调控的特征。本研究对磷酸肌醇5-磷酸酶基因功能的初步研究为磷脂信号途径中负调控组分的分析提供了参考依据。     

脐带问充质干细胞联合表皮生长因子治疗III、Ⅳ期压疮的临床研究

目的：探讨脐带间充质干细胞移植联合表皮生长因子治疗III、Ⅳ期压疮的临床效果。方法：选取我院2011-2012年收治的III、Ⅳ期压疮患者143例为研究对象,随机分为对照组、实验一组和实验二组。对照组30例压疮患者行常规换药,实验一组58例压疮患者应用脐带间充质干细胞移植联合表皮生长因子治疗,实验二组55例压疮患者仅应用表皮生长因子治疗。治疗后,比较三组患者愈合时间及愈合效果。结果：实验一组和实验二组的显效时间和愈合时间均较对照组显著缩短,且实验一组的显效时间和愈合时间较实验二组更短,差异均有统计学意义（均P〈0．05）。实验一组的治愈率显著高于对照组（P〈0．05）,而与实验二组比较无统计学差异（P〉0．05）,实验二组的治愈率与对照组比较无统计学差异（P〈0．05）。实验一组的总有效率显著高于对照组和实验二组（P〈0．05）,而实验二组的总有效率与对照组比较无统计学差异（P〉0．05）。结论：脐带间充质干细胞移植联合表皮生长因子较单用表皮生长因子及常规治疗方法更好的改善III、Ⅳ期压疮创面的愈合,避免患者组织感染,提高压疮患者的生活质量。     

Mechanisms of bronchopulmonary dysplasia

Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting premature infants with long term effect on lung function into adulthood. Multiple factors are involved in the development of BPD. This review will summarize the different mechanisms leading to this disease and highlight recent bench and clinical research targeted at understanding the role of the mesenchyme (both its cellular and extracellular components) in the pathogenesis of BPD.     

一株海洋放线菌的鉴定及其促生作用机理

【背景】海洋放线菌BM-2是本实验室从连云港海域分离得到的一株具有抗菌和促生作用的优良菌株,具有良好的开发应用前景。【目的】明确海洋放线菌BM-2的分类地位,揭示该菌株的促生作用机理,为菌株的开发应用提供理论依据。【方法】通过形态观察、生理生化特性和16S rRNA基因序列分析,对海洋放线菌BM-2菌株进行种属鉴定;采用透明圈法、平板划线法测定BM-2菌株解磷、解钾作用、固氮作用和产植酸酶、1-氨基环丙烷-1-羧基(1-aminocyclopropane-1-carboxylate,ACC)脱氨酶的能力;运用沙尔科夫斯基反应(Salkowski法)和铬天青(chromeazurol S,CAS)法分别测定菌株产吲哚乙酸(indole acetic acid,IAA)和产铁载体的能力。【结果】培养特征、菌落形态观察及生理生化试验结果表明,BM-2菌株符合链霉菌属(Streptomyces)的特征,16S rRNA基因序列与GenBank中栗褐链霉菌(Streptomyces badius)的序列相似性为99.72%;BM-2菌株具有固氮和解有机磷活性,能够产生ACC脱氨酶、铁载体和IAA。【结论】BM-2菌株为栗褐连霉菌(Streptomyces badius),固氮、解有机磷作用以及产生ACC脱氨酶、IAA可能是该菌株的促生作用机制。     

Environmental Oxygen is a Key Modulator of Development and Evolution: From Molecules to Ecology

Oxygen is a key regulator of both development and homeostasis and a promising candidate to bridge the influence of the environment and the evolution of new traits. To clarify the various ways in which oxygen may modulate embryogenesis, its effects are reviewed at distinct organizational levels. First, the role of pathways that sense dioxygen levels and reactive oxygen species are reviewed. Then, the effects of microenvironmental oxygen on metabolism, stemness, and differentiation throughout embryogenesis are discussed. Last, the interplay between ecology and development are reexamined with a focus on the evolution of tetrapods, including during the emergence of a novel mechanism that shapes amniote limbs—interdigital cell death. Both genetic and environmental components work together during the formation of organisms, highlighting the importance of a multidisciplinary approach for understanding the evolution of new traits.